BRCA2 and ovarian carcinoma: The present meta-analysis with the largest number of patients investigated both survival (OS) and progression outcomes (PFS) for ovarian cancer, incorporating not only the general BRCA mutation status but also two subtypes, including BRCA1 and BRCA2 mutation status.